Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; titanium dioxide; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod gxp is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod arw is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod-scp is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; titanium dioxide; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod-fbm is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fingolimod hydrochloride, quantity: 560 microgram (equivalent: fingolimod, qty 500 microgram) - capsule, hard - excipient ingredients: polacrilin potassium; crospovidone; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod ran is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fingolimod hydrochloride, quantity: 560 microgram (equivalent: fingolimod, qty 500 microgram) - capsule, hard - excipient ingredients: polacrilin potassium; crospovidone; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod rbx is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fingolimod hydrochloride, quantity: 0.56 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin - fingolimod gh is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fingolimod hydrochloride, quantity: 0.56 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin - fingolimod an is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fingolimod hydrochloride, quantity: 0.56 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin - fingolimod ameda is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fingolimod hydrochloride, quantity: 0.56 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin - fingolimod astron is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.